Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
DOI
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Semaglutid in der Behandlung von Menschen mit Adipositas,Herzinsuffizienz mit erhaltener Ejektionsfraktion und Diabetes mellitus Typ 2.
Semaglutide in the treatment of people with obesity, heart failure with preserved ejection fraction, and type 2 diabetes mellitus.
Diabetologie, DOI: 10.1007/s11428-025-01316-y (2025)
Publication type
Article: Journal article
Document type
Editorial
Language
german
Publication Year
2025
HGF-reported in Year
2025
ISSN (print) / ISBN
2731-7447
e-ISSN
2731-7455
Journal
Diabetologie, Die
Publisher
Springer
Publishing Place
Tiergartenstrasse 17, D-69121 Heidelberg, Germany
Reviewing status
Peer reviewed
Institute(s)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Helmholtz AI - FZJ (HAI - FZJ)
Helmholtz AI - FZJ (HAI - FZJ)
POF-Topic(s)
30201 - Metabolic Health
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-506500-001
WOS ID
001476723300001
Scopus ID
105004188683
Erfassungsdatum
2025-05-13